CA2268023A1 - Circularly permuted polypeptides as novel stem cell factor receptor agonists - Google Patents

Circularly permuted polypeptides as novel stem cell factor receptor agonists Download PDF

Info

Publication number
CA2268023A1
CA2268023A1 CA002268023A CA2268023A CA2268023A1 CA 2268023 A1 CA2268023 A1 CA 2268023A1 CA 002268023 A CA002268023 A CA 002268023A CA 2268023 A CA2268023 A CA 2268023A CA 2268023 A1 CA2268023 A1 CA 2268023A1
Authority
CA
Canada
Prior art keywords
ser
seq
cells
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002268023A
Other languages
English (en)
French (fr)
Inventor
Charles A. Mcwherter
Yiqing Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2268023A1 publication Critical patent/CA2268023A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002268023A 1996-10-25 1997-10-23 Circularly permuted polypeptides as novel stem cell factor receptor agonists Abandoned CA2268023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2916596P 1996-10-25 1996-10-25
US60/029,165 1996-10-25
PCT/US1997/018701 WO1998018924A1 (en) 1996-10-25 1997-10-23 Circularly permuted polypeptides as novel stem cell factor receptor agonists

Publications (1)

Publication Number Publication Date
CA2268023A1 true CA2268023A1 (en) 1998-05-07

Family

ID=21847588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268023A Abandoned CA2268023A1 (en) 1996-10-25 1997-10-23 Circularly permuted polypeptides as novel stem cell factor receptor agonists

Country Status (6)

Country Link
US (1) US5969105A (enExample)
EP (1) EP0941321A1 (enExample)
JP (1) JP2001502915A (enExample)
AU (1) AU734594B2 (enExample)
CA (1) CA2268023A1 (enExample)
WO (1) WO1998018924A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248319B1 (en) 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
MXPA01005564A (es) * 1998-12-04 2003-07-14 Naval Medical Res Ct Celulas del endotelio cerebral humano en medio de crecimiento y metodo para expansion de celulas de tallo de medula osea cd34+cd38-nativas.
AU1350801A (en) * 1999-10-27 2001-05-08 Frances Arnold Production of functional hybrid genes and proteins
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002064755A2 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
CA2505534A1 (en) 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
CA2607844C (en) 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
WO2007079184A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
PL2120977T3 (pl) 2007-02-12 2013-12-31 Anthrogenesis Corp Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US8263065B2 (en) 2007-09-28 2012-09-11 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
DK2329012T3 (da) 2008-08-20 2020-08-24 Celularity Inc Behandling af slagtilfælde under anvendelse af isolerede placentaceller
EP3172963B1 (en) 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
DK2331109T3 (da) 2008-08-22 2013-09-08 Anthrogenesis Corp Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
EP3190179A1 (en) 2009-07-02 2017-07-12 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
SG177651A1 (en) * 2009-07-13 2012-03-29 Biogencell Ltd Method for using directing cells for specific stem/progenitor cell activation and differentiation
KR20120115602A (ko) 2010-01-26 2012-10-18 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 골 관련 암의 치료
PT2556145T (pt) 2010-04-07 2016-10-25 Anthrogenesis Corp Angiogénese usando células estaminais placentárias
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
KR20230096132A (ko) 2010-07-13 2023-06-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US8956870B2 (en) 2012-01-19 2015-02-17 Biogencell, Ltd. Method for using directing cells for specific stem/progenitor cell activation and differentiation
EP2858672B1 (en) 2012-06-08 2018-04-04 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
JP2016506968A (ja) 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション 胎盤由来のナチュラルキラー細胞
JPWO2023145860A1 (enExample) * 2022-01-27 2023-08-03

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005795A1 (en) * 1989-10-16 1991-05-02 Amgen Inc. Stem cell factor
EP0992579B1 (en) * 1989-10-16 2008-08-06 Amgen Inc. Stem cell factor
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
PT789761E (pt) * 1994-11-04 2005-09-30 Applied Research Systems Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica
IL123832A0 (en) * 1995-10-05 1998-10-30 Searle & Co Multi-functional hematopoietic receptor antagonists
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method

Also Published As

Publication number Publication date
EP0941321A1 (en) 1999-09-15
WO1998018924A1 (en) 1998-05-07
AU4905797A (en) 1998-05-22
JP2001502915A (ja) 2001-03-06
AU734594B2 (en) 2001-06-21
US5969105A (en) 1999-10-19

Similar Documents

Publication Publication Date Title
AU734594B2 (en) Circularly permuted polypeptides as novel stem cell factor receptor agonists
US20060172932A1 (en) Novel erythropoietin receptor agonists
US6660257B1 (en) Circular permuteins of flt3 ligand
US6730303B1 (en) Fused G-CSF and IL-3 proteins and uses thereof
AU717733B2 (en) Novel G-CSF receptor agonists
KR100456212B1 (ko) 다기능성조혈수용체아고니스트
US6358505B1 (en) G-CSF receptor agonists
CA2268742A1 (en) Multi-functional chimeric hematopoietic receptor agonists
WO1997012985A9 (en) Multi-functional hematopoietic receptor agonists
AU722759B2 (en) Novel C-MPL receptor agonists
US20070081979A1 (en) Multi-functional chimeric hematopoietic receptor agonists
AU703627B2 (en) Interleuken-3 (IL-3) receptor agonists
MXPA99003875A (en) NOVEL flt-3 RECEPTOR AGONISTS
JP2002515729A (ja) 新規ｇ−ｃｓｆ受容体アゴニスト
MXPA99003874A (es) Agonistas del receptor de eritropoyetina circularmente permutados
CZ346799A3 (cs) Chimérické proteiny jako flt3 ligandy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20071023